Collaborating On Common Challenges

The Think Tank on Advancing Precision Medicine in Rare Cancers is a highly-interactive meeting that brings together clinicians, researchers, industry representatives, advocates, and patients to collaborate on common challenges in rare cancer research and treatment.

Leveraging the successful Think Tank model established through over a decade of TargetCancer Foundation meetings, it creates a collaborative environment where diverse perspectives and ideas thrive. This meeting also builds on the progress made through TargetCancer Foundation’s TCF-001 TRACK study, a nationwide, decentralized, patient-driven clinical trial studying precision medicine in rare cancers.

Think Tank on Advancing Precision Medicine in Rare Cancers
Collage of Think Tank participants for rare cancer research
Decorative Sparkles

Save the Date for our 2024 Meeting!

November 20, 2024 ⏐Boston, MA
Details to come

Think Tank attendees group photo

What participants are saying

This was a fantastic #RareCancer #PrecisionMedicine meeting @targetcancer in Boston! So much enthusiasm from patients and patient advocates to move the field forward.

Vivek Subbiah MD

Vivek Subbiah, MD
Sarah Cannon Research Institute
Originally posted on Twitter

This is genuinely the best rare cancer meeting I have ever attended.

Vivek Subbiah MD

Razelle Kurzrock, MD
Froedtert and Medical College of Wisconsin

…thank you for allowing me to be a part of the discussion of challenges, goals, opportunities and best practices in addressing the needs of patients facing rare cancers. What a wonderful group of humans you gathered. I was so inspired.

Vivek Subbiah MD

Katie Ortman Doble
Patient Keynote Speaker,
2023 Think Tank on Advancing Precision Medicine in Rare Cancers

View and download materials from past meetings

TargetCancer Icon, White

TCF-001 TRACK Live Molecular Tumor Board 2023: Osteosarcoma

Presented at the TargetCancer Foundation Think Tank on Advancing Precision Medicine in Rare Cancers, November 15, 2023, Boston MA

We are grateful to our industry partners for supporting these meetings and for their dedication to developing treatments for patients with rare cancers.